Log in to save to my catalogue

Economic burden of short-acting beta-2 agonist (SABA) overuse among asthma patients in Türkiye: a co...

Economic burden of short-acting beta-2 agonist (SABA) overuse among asthma patients in Türkiye: a co...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ae353dc84458405b82aede92b5ce0ae1

Economic burden of short-acting beta-2 agonist (SABA) overuse among asthma patients in Türkiye: a cost analysis with respect to the updated GINA treatment recommendations

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

This cost of illness study aimed to determine economic burden of short-acting β2-agonist (SABA) overuse in Türkiye from payer perspective with respect to the updated GINA 2022 treatment recommendations.
A total of 3,034,879 asthma patients comprised the study population, via estimations extrapolated from the Türkiye arm of the global SABINA III...

Alternative Titles

Full title

Economic burden of short-acting beta-2 agonist (SABA) overuse among asthma patients in Türkiye: a cost analysis with respect to the updated GINA treatment recommendations

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_ae353dc84458405b82aede92b5ce0ae1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ae353dc84458405b82aede92b5ce0ae1

Other Identifiers

ISSN

1471-2466

E-ISSN

1471-2466

DOI

10.1186/s12890-024-03327-9

How to access this item